Allogene Therapeutics Files 8-K for Other Event
Ticker: ALLO · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, other-event
Related Tickers: ALLO
TL;DR
ALLO filed an 8-K for an 'Other Event' on 9/26. Details TBD.
AI Summary
Allogene Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting an "Other Event" that occurred on September 26, 2025. The filing does not contain specific details about the nature of this event, only its occurrence and reporting date.
Why It Matters
This filing indicates a material event has occurred for Allogene Therapeutics, requiring disclosure to investors, though the specific nature of the event is not yet detailed.
Risk Assessment
Risk Level: medium — The filing of an 8-K for an 'Other Event' suggests a material development, but the lack of immediate detail creates uncertainty for investors.
Key Players & Entities
- Allogene Therapeutics, Inc. (company) — Registrant
- 0001628280-25-044828 (filing_id) — Accession Number
- 20251014 (date) — Filing Date
- 20250926 (date) — Date of Earliest Event Reported
FAQ
What specific event is Allogene Therapeutics reporting in this 8-K filing?
The filing is categorized under 'Other Events' and does not provide specific details about the nature of the event that occurred on September 26, 2025.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on October 14, 2025.
What is the earliest date for which an event is being reported?
The earliest date for which an event is reported is September 26, 2025.
What is the company's principal executive office address?
The address of the principal executive offices is 210 East Grand Avenue, South San Francisco, California 94080.
What is the company's IRS Employer Identification Number (EIN)?
The company's EIN is 82-3562771.
Filing Stats: 728 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2025-10-10 17:31:11
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value per share ALLO The Nasdaq Sto
Filing Documents
- allo-20250926.htm (8-K) — 25KB
- 0001628280-25-044828.txt ( ) — 138KB
- allo-20250926.xsd (EX-101.SCH) — 2KB
- allo-20250926_lab.xml (EX-101.LAB) — 21KB
- allo-20250926_pre.xml (EX-101.PRE) — 12KB
- allo-20250926_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALLOGENE THERAPEUTICS, INC. By: /s/ David Chang, M.D., Ph.D. David Chang, M.D., Ph.D. President, Chief Executive Officer Dated: October 10, 2025